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Abstract 
Bee venom (BV) or apitoxin is a complex mixture of substances with reported biological 
activity. In the present work, five bee venom samples obtained from Apis mellifera iberiensis 
from the Northeast Portugal (two different apiaries) were chemically characterized and evaluated 
for their antioxidant, anti-inflammatory and cytotoxic properties. The LC/DAD/ESI-MSn 
analysis of the samples showed that melittin was the most abundant compound, followed by 
phospholipase A2 and apamin. All the samples revealed antioxidant and anti-inflammatory 
activity but without a direct relation with any of the individual chemical components identified. 
The results highlight that there are specific concentrations (present in BV5) in which these 
compounds are more active. The BV samples showed similar cytotoxicity for all the tested 
tumour cell lines (MCF-7, NCI-H460, HeLa and HepG2), being MCF-7 and HeLa the most 
susceptible ones. Nevertheless, the studied samples seem to be suitable to treat breast, 
hepatocellular and cervical carcinoma because at the active concentrations, the samples were not 
toxic for non-tumour cells (PLP2). Regarding the non-small cell lung carcinoma, BV should be 
used under the toxic concentration for non-tumour cells. Overall, the present study corroborates 
the enormous bioactive potential of BV being the first report on samples from Portugal. 
 




Bee venom (BV) or apitoxin, produced in the venom gland of the bee (Apis mellifera), located in 
the abdominal cavity, is a complex mixture of substances with reported biological activity (Liu et 
al., 2002; Oršolić, 2009; Oršolić, 2012). The active compounds of the BV have been described as 
proteins and peptides (melittin (MEL), apamin (APA), adolapin, the mast cell degranulating 
peptide, secapin, procamine, protease inhibitor, tertiapin and other small peptides), enzymes 
(phospholipase A2 (PLA2), hyaluronidase, acid phosphomonoesterase, lysophopholipase and α-
glucosidase), as well as non-peptide components, such as physiologically active amines 
(histamine, dopamine and noradrenalin), amino acids (aminobutyric acid and α-amino acids), 
sugars (glucose and fructose), phospholipids and volatile compounds (Park et al., 2010; Gajski 
and Garaj-Vrhovac, 2013; Liu et al., 2014). Within these mixture, the major components of BV 
are histamine, catecholamines, polyamines, melittin and PLA2 (Oršolić et al., 2003). 
BV has been used as a traditional medicine to treat chronic inflammatory (arthritis, rheumatism 
and back pain) (Chang and Bliven, 1979; Kwon et al., 2001; Kim et al., 2003; Son et al., 2007; 
Park et al., 2008; Vasileiadou et al., 2010) and skin (Escrig et al., 1997; Han et al., 2012) 
diseases. In fact, the anti-inflammatory properties of BV samples from different origins such as 
Egypt (Amin and Abdel-Raheem, 2014), Korea (Park et al., 2007; Park et al., 2008; Lee et al., 
2009), USA (Chang and Bliven, 1979) and even commercial samples (Jang et al., 2005; Moon et 
al., 2007; Yoon et al., 2008) have been reported in apitherapy. Furthermore, BV individual 
compounds have also shown the same properties, as in the case of mast cell degranulating 
peptide (Banks et al., 1990), MEL (Moon et al., 2006; Park et al., 2007; Srivastava et al., 2012; 
Rayahin et al., 2014) and PLA2 (Ximenes et al., 2012), which are related with their capacity to 
reduce pro-inflammatory cytokines such as tumor necrosis factor (TNF-α) and interleukins (IL-
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1β, or IL-6), as well as other inflammatory mediators including prostaglandin E2 (PGE2) and 
nitric oxide (NO), which are synthesized by cyclooxygenase (COX) and inducible nitric oxide 
synthase (iNOS), respectively. The production of these mediators has been demonstrated in 
several inflamed tissues involved in the pathogenesis of several diseases, such as atherosclerosis, 
obesity, metabolic syndrome, diabetes, neurodegenerative diseases, and several types of cancers 
(Nam et al., 2003; Jang et al., 2005; Janik et al., 2007; Karimzadeh et al., 2013; Mohammadi et 
al., 2015). 
The anticancer effects of commercial BV (Xiu et al., 2002; Moon et al., 2006; Lee et al., 2007; 
Gajski et al., 2014; Kim et al., 2015), BV samples from Iran (Alizadehnohi et al., 2012) and 
Slovenia (Oršolić et al., 2003; Oršolić, 2009) and individual components such as PLA2 
(Ferguson and Duncan, 2009) and MEL (Hu et al., 2006; Huh et al., 2012) have also been 
described. These properties are related with induction of apoptosis and necrosis (Liu et al., 2014) 
and cytotoxic effects in different types of cell lines, including prostate, breast, kidney, bronchial 
epithelium (Huh et al., 2012), lung (Putz et al., 2006), ovarian (Alizadehnohi et al., 2012), colon 
(Ferguson and Duncan, 2009), bladder (Ip et al., 2012), leukemic (Moon et al., 2006), cervical 
(Oršolić et al., 2009; Gajski and Garaj-Vrhovac, 2013; Gajski et al., 2014) and laryngeal 
carcinoma	(Gajski and Garaj-Vrhovac, 2013), but also in non-tumor cells such as lymphocytes 
(Lee et al., 2007; Garaj-Vrhovac and Gajski, 2009). 
Antimutagenic (Varanda et al., 1999), antinociptive (Baek et al., 2006), and radioprotective 
(Garaj-Vrhovac and Gajski, 2009) effects are among other bioactive properties of BV, together 
with the low explored antioxidant potential of this natural matrix. A few studies report the 
antioxidant effects of BV samples from Korea (Han et al., 2010) and USA (Rekka et al., 1990), 
and of PLA2 (Snyder et al., 1985). 
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In the present work, five bee venom samples obtained from Apis mellifera iberiensis from the 
Northeast Portugal were chemically characterized and evaluated for their antioxidant, anti-
inflammatory and cytotoxic properties. 
 
2. Materials and methods	
2.1. Samples collection 
Five distinct bee venom samples were collected between May and July of 2014 from Apis 
mellifera iberiensis hives located in two different apiaries near Bragança (BV1-5), in the 
Northeast region of Portugal. The physical distance between the two apiaries (BV1-4 in 
“Milhão” (41º47’39” N; 6º39’10” W) ; BV5 in “Aveleda” (41º54’9” N; 6º40’2” W)) is about 12 
Km. For the sample collection a BeeWhisper 0412 bee venom collector (IGK Electronics, 
Bulgaria) was placed at the entrance of the hive. When the honeybees covered the entire surface 
of the collector frame and came into contact with the wire grid, a mild electrical impulse shock 
(1.8 V) was applied. The immediate response of the honeybees was generated, and they stung the 
surface of the collector glass. Every 50 seconds, the device paused for additional 10 seconds. 
After 40 minutes of working time, the device turned off automatically. That was the maximum 
time applied for bee venom collection, per colony, in one session. Each sample corresponds to 
bee venom collected from 5 neighbor colonies. After the collection period, the bee venom was 
scraped off from the glass with a sharp scraper. The bee venom was then freeze-dried and stored 
at -18 oC until further analysis.	
 
2.2. Standards and reagents 
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Apamin from bee venom (purity 98.3%) was obtained from CalBiochem (San Diego, CA, USA). 
Phospholipase A2 from bee venom (activity: 1775 units mg-1 solid), cytochrome c from equine 
heart (purity ≥ 95%), trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), 
lipopolysaccharide (LPS), dexamethasone, sulforhodamine B, trypan blue, trichloro acetic acid 
(TCA) and Tris were purchased from Sigma-Aldrich (St. Louis, MO, USA). Melittin from bee 
venom (purity: 67%) was obtained from Latoxan (Valence, France). Formic acid was from 
Panreac (Barcelona, Spain), while HPLC grade acetonitrile was from Fisher Scientific UK 
(Loughborough, Leics, UK). 2,2-Diphenyl-1-picrylhydrazyl (DPPH) was obtained from Alfa 
Aesar (Ward Hill, USA). RAW 264.7 cells were purchased from ECACC (“European Collection 
of Animal Cell Culture”) (Salisbury, UK) and DMEM from Hyclone (Logan, Utah, US). The 
Griess Reagent System Kit was purchased from Promega (Madison, WI, USA). Dulbecco’s 
modified Eagle’s medium (DMEM), hank’s balanced salt solution (HBSS), fetal bovine serum 
(FBS), L-glutamine, trypsin-EDTA, penicillin/streptomycin solution (100 U/mL and 100 mg/ 
mL, respectively) were purchased from Gibco Invitrogen Life Technologies (California, USA). 
Water was treated in a Milli-Q water purification system (TGI Pure Water Systems, USA). 
 
2.3. Chemical characterization of the samples by LC/DAD/ESI-MSn  
The LC/DAD/ESI-MSn analyses were performed on a Dionex Ultimate 3000 UPLC instrument 
(Thermo Scientific, USA) equipped with a diode-array detector and coupled to a mass detector. 
The chromatographic system consisted of a quaternary pump, an autosampler maintained at 5 ºC, 
a degasser, a photodiode-array detector, an automatic thermostatic column compartment. The 
chromatographic separation was carried out according with previously described work with some 
modifications on a XSelect CSH130 C18, 100mm×2.1 mm id, 2.5 µm XP column (Waters, 
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Milford, MA) and its temperature was maintained at 30 ºC. The mobile phase consisted of (A) 
0.1% (v/v) formic acid in water and (B) 0.1% (v/v) formic acid in acetonitrile, which were 
previously degassed and filtrated. The solvent gradient started with 100% A, reaching 60% B at 
12 min, 100% B at 15 min and return to the initial conditions. The flow rate was 0.3 mL/min, 
with an injection volume of 40 µL. Spectral data for all peaks were accumulated in the range 
190–500 nm. Cytochrome c, as the internal standard (IS), was prepared in deionized water at the 
concentration of 25 µg/mL. For the analysis, the lyophilized bee venom (3 mg) was dissolved in 
10 mL of internal standard. Each sample was filtered through a 0.2 µm nylon membrane 
(Whatman). Bee venom quantification was achieved using calibration curves for apamin (2-60 
µg/mL; y = 0.032x+0.012), phospholipase A2 (4-120 µg/mL; y = 0.042x+0.045), melittin (21-
335 µg/mL; y = 0.032x+0.133). The standard solutions were prepared by dissolving them in IS 
solution for the desire concentration. 
The mass spectrometer was operated in the positive ion mode using Linear Ion Trap LTQ XL 
mass spectrometer (Thermo Scientific, San Jose, CA, USA) equipped with an ESI source. 
Typical ESI conditions were nitrogen sheath gas 35 psi, spray voltage 3.5 kV, source 
temperature 300 °C, capillary voltage 20 V, and the tube lens offset was kept at voltage of 74 V. 
The full scan covered the mass range from m/z 50 to 2000. The collision energy used was 30 
(arbitrary units). Data acquisition was carried out with Xcalibur® data system (Thermo 
Scientific, San Jose, CA, USA). 
 
2.4. Evaluation of antioxidant properties 
The BV samples were dissolved in water at 5 mg/mL and then submitted to further dilutions 
from 5 to 0.02 mg/mL. DPPH radical-scavenging activity was evaluated by using an ELX800 
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microplate reader (Bio-Tek Instruments, Inc; Winooski, VT, USA), and calculated as a 
percentage of DPPH discolouration using the formula:  [(ADPPH-AS)/ADPPH] x 100, where AS is 
the absorbance of the solution containing the sample at 515 nm, and ADPPH is the absorbance of 
the DPPH solution. Reducing power was evaluated by the capacity to convert Fe3+ into Fe2+, 
measuring the absorbance at 690 nm in the microplate reader mentioned above. Inhibition of β-
carotene bleaching was evaluated though the β-carotene/linoleate assay; the neutralization of 
linoleate free radicals avoids β-carotene bleaching, which is measured by the formula: β-carotene 
absorbance after 2h of assay/initial absorbance) x 100. Lipid peroxidation inhibition in porcine 
(Sus scrofa) brain homogenates was evaluated by the decreasing in thiobarbituric acid reactive 
substances (TBARS); the colour intensity of the malondialdehyde-thiobarbituric acid (MDA-
TBA) was measured by its absorbance at 532 nm; the inhibition ratio (%) was calculated using 
the following formula: [(A - B)/A] × 100%, where A and B were the absorbance of the control 
and the sample solution, respectively (Fernandes et al., 2013). The results were expressed in 
EC50 values (sample concentration providing 50% of antioxidant activity or 0.5 of absorbance in 
the reducing power assay). Trolox was used as positive control.	
 
2.5. Evaluation of anti-inflammatory properties 
The BV samples were dissolved in water at 4 mg/mL and then submitted to further dilutions 
from 4 to 0.0625 mg/mL. The mouse macrophage-like cell line RAW264.7 was cultured in 
DMEM medium supplemented with 10% heat-inactivated foetal bovine serum and glutamine at 
37°C under 5% CO2, in humidified air. For each experiment, cells were detached with a cell 
scraper. Under our experimental cell density (5 x 105 cells/mL), the proportion of dead cells was 
less than 1%, according to Trypan blue dye exclusion tests. Cells were seeded in 96-well plates 
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at 150,000 cells/well and allowed do attach to the plate overnight. Then, cells were treated with 
the different concentrations of each of the extracts for 1 h. Dexamethasone (50 µM) was used as 
a positive control for the experiment. The following step was stimulation with LPS (1 µg/mL) 
for 18 h. The effect of the tested samples in the absence of LPS was also evaluated, in order to 
observe if they induced changes in NO basal levels. In negative controls, no LPS was added. 
Both extracts and LPS were dissolved in supplemented DMEM. For the determination of nitric 
oxide, a Griess Reagent System kit was used, which contains sulfanilamide, NED and nitrite 
solutions. The cell culture supernatant (100 µL) was transferred to the plate in duplicate and 
mixed with sulfanilamide and NED solutions, 5-10 minutes each, at room temperature. The 
nitrite produced was determined by measuring the optical density at 515 nm, in the microplate 
reader referred above, and was compared to the standard calibration curve.	
The results were expressed in percentages of inhibition of NO production in comparison with the 
negative control (100%) and EC50 values (sample concentration providing 50% of inhibition of 
NO production) were also estimated. 
 
2.6. Evaluation of cytotoxic properties 
The BV samples were dissolved in water at 4 mg/mL and then submitted to further dilutions 
from 4 to 0.0625 mg/mL. Four human tumor cell lines were used: MCF-7 (breast 
adenocarcinoma), NCI-H460 (non-small cell lung cancer), HeLa (cervical carcinoma) and 
HepG2 (hepatocellular carcinoma). Cells were routinely maintained as adherent cell cultures in 
RPMI-1640 medium containing 10% heat-inactivated FBS and 2 mM glutamine (MCF-7, NCI-
H460 HeLa and HepG2 cells), at 37 ºC, in a humidified air incubator containing 5% CO2. Each 
cell line was plated at an appropriate density (7.5 × 103 cells/well for MCF-7 and NCI-H460 or 
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1.0 × 104 cells/well for HeLa and HepG2) in 96-well plates. Sulforhodamine B assay was 
performed according to a procedure previously described by the authors (Barros et al., 2013). 
For evaluation of the cytotoxicity in non-tumor cells, a cell culture was prepared from a freshly 
harvested porcine liver obtained from a local slaughterhouse, according to a procedure 
established by the authors (Abreu et al., 2011); it was designed as PLP2. Cultivation of the cells 
was continued with direct monitoring every two to three days using a phase contrast microscope. 
Before confluence was reached, cells were subcultured and plated in 96-well plates at a density 
of 1.0×104 cells/well, in DMEM medium with 10% FBS, 100 U/mL penicillin and 100 µg/mL 
streptomycin. Ellipticine was used as positive control and the results were expressed in GI50 
values (concentration that inhibited 50% of the net cell growth). 	
 
2.7. Statistical analysis 
For all the experiments three samples were analyzed and all the assays were carried out in 
triplicate. The results are expressed as mean values ± standard deviation (SD). The differences 
between the different samples were analyzed using one-way analysis of variance (ANOVA) 
followed by Tukey’s honestly significant difference post hoc test with α = 0.05, coupled with 
Welch’s statistic. This procedure was carried out using SPSS v. 22.0 program.  		 	
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3. Results and discussion 
The chemical components identified in the five studied BV samples are presented in Table 1. 
Melittin was the most abundant compound in all the samples, while apamin was the component 
at the lowest concentration (Table 1, Fig. 1). In fact, mellitin has been reported by different 
authors as the main constituent of BV (Park et al., 2012; Cho et al., 2013). BV2 gave the highest 
levels of mellitin (86.72 ± 0.50 µg/mL), phospholipase A2 (11.36 ± 0.18 µg/mL) and apamin 
(1.80 ± 0.03 µg/mL), followed by BV4. On the other hand, BV5 and, mainly, BV1 showed the 
lowest concentrations in all the compounds. Although the individual amount changes with the 
samples, it is evident that the proportion of each compound, normalized to the overall mass, is 
similar, with mellitin, phospholipase A2 and apamin representing, in all samples, 86%, 13% and 
2%, respectively. This stresses out that the presence of other substances in the overall mass of the 
bee venom varies for each sample. Additionally, samples BV1 and BV5 were both collected 
earlier in May, which corresponds to the beginning of the production season. This feature may 
influence the age of the honeybees, and therefore the apitoxin composition, since it is well 
known that the synthesis and composition of bee venom is age dependent, with lower melittin 
content found in younger bees (Dong et al., 2015). 
All the samples revealed antioxidant and anti-inflammatory activity and, apparently, not related 
to none of the individual components identified and quantified in the samples. BV5 proved to 
have the highest free radicals scavenging activity, reducing power, lipid peroxidation inhibition 
and also the highest capacity to inhibit NO production (Table 2). Among the studied BV 
samples, BV5 was the unique that was collected in a different apiary. It should be highlighted 
that the anti-inflammatory activity of all BV samples (EC50 values < 8 µg/mL) was higher than 
the positive control, dexamethasone (EC50 value=15.5±1.96 µg/mL; Table 2). 
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The lack of correlations between the concentration of mellitin, phospholipase A2 or apamin, and 
the results of the in vitro antioxidant and anti-inflammatory activities evidences that there are 
specific concentrations in which these compounds are more active. At higher or lower 
concentrations, the mentioned activities decrease probably due to antagonistic effects.  
Curiously, a pro-inflammatory effect of samples in BV3, BV4 and BV5 was observed at the 
lowest tested concentration (increase in the NO levels in comparison with the negative control 
(>100% at 1 µg/mL; Figure 2). To our knowledge this kind of effect was not previously reported, 
being only described the inhibition of NO formation in Raw 264.7 cells by BV samples in the 
range of 0.1-2 µg/mL (Lee et al., 2009), 0.5-2 µg/mL (Moon et al., 2007), 0.5-5 µg/mL (Park et 
al., 2007) and 1-20 µg/mL (Jang et al., 2005), as in the present study (tested concentrations: 1-15 
µg/mL). In vivo experiments with Lewis rats also support the anti-inflammatory effects of BV 
samples (Chang and Bliven, 1979; Amin and Abdel-Raheem, 2014). Regarding the antioxidant 
effects of BV samples, they have been related with the capacity to inhibit the lipid peroxidation 
process (Rekka et al., 1990) and to increase superoxide dismutase (SOD) activity (Han et al., 
2010).  
The studied BV samples showed similar cytotoxicity for all the tested tumour cell lines: breast 
(MCF-7), non-small cell lung (NCI-H460), cervical (HeLa) and HepG2 (hepatocellular) 
carcinoma (Table 3). MCF-7 and HeLa were the most susceptible cell lines to the action of BV 
samples (GI50 values < 5 µg/mL). In the case of HeLa cell line, a GI50 value in the same 
magnitude was reported by Orsolić (2009) for BV from Slovenia (3 µg/mL). Otherwise, 
commercial BV samples revealed lower activity against HeLa cells (GI50=9.7 µg/mL (Kim et al., 
2015) and ~20% of cellular viability at 60 µg/mL (Gajski et al., 2014). The antitumor effects of 
BV samples were also demonstrated by in vivo experiments (Liu et al., 2002; Oršolić, 2003). 
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It should be highlighted that despite the toxicity observed for BV samples in relation to non-
tumour liver cells (PLP2; Table 3), at the GI50 concentrations obtained for tumour cell lines, 
none of the samples was toxic for PLP2, except for the case of NCI-H460 in which the cytotoxic 
concentrations (GI50 values between 16.00 ± 2.34 and 19.68± 1.80 µg/mL) were higher than the 
ones observed in PLP2 (GI50 values between 10.11 ± 0.91 and 15.03 ± 0.28 µg/mL). Therefore, 
the studied samples seem to be suitable to treat breast, hepatocellular and cervical carcinoma, 
and regarding the non-small cell lung carcinoma, it should be used under the concentration toxic 
for non-tumour cells. The toxicity of BV for non-tumour cells, such as lymphocytes was also 
previously reported by different authors (Gajski and Garaj-Vrhovac, 2008; Garaj-Vrhovac and 
Gajski, 2008; Mohammadi et al., 2015). 
 
4. Conclusions 
Overall, this study demonstrates the broad bioactive potential of BV including antioxidant, anti-
inflammatory and cytotoxic activities, being the first report for Portuguese samples. Despite the 
identification of the most abundant molecules in BV, some other minor compounds, together 
with synergistic/antagonistic effects at specific concentrations, could be involved in the reported 
bioactivities, contributing to different results among BV samples.  
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Fig. 1. Representative chromatographic profile at 220 nm of A. mellifera iberiensis venom: 1- 
apamin; 2- phospholipase A2; IS- internal standard (cytochrome C, 25 µg/mL); 3-melittin. 
 
Fig. 2. Nitric oxide production as function of concentration of A. mellifera iberiensis venom 
(BV1-5). As the production of oxide nitric is proportional to the inflammatory process, a 





























 Chemical characterization of the bee venom (BV) samples by LC/DAD/ESI-MSn analysis. 
 
 BV 1	 BV 2	 BV 3	 BV 4	 BV 5	
Apamin (µg/mL)	 0.94±0.01d	1.80±0.03ab	1.61±0.17b	 1.95±0.02a	 1.25±0.04c	
Phospholipase A2 (µg/mL)	 4.98±0.01d	11.36±0.18a	9.02±0.62c	10.08±0.34b	5.98±0.11d	
Melittin(µg/mL)	 35.64±0.09e	86.72±0.50a	70.58±3.99c	80.74±0.34b	52.20±0.66d	
 
In each row different letters mean significant differences between samples (p<0.05).  
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Table 2 
In vitro antioxidant and anti-inflammatory activities of the bee venom (BV) samples. 
 BV 1	 BV 2	  BV 3	 BV 4	 BV 5 
Antioxidant activity (EC50 values, µg/mL)   
DPPH scavenging activity 487±7b 451±6c	 491±1b	 512±16a	 346±4d	
Reducing power  326±16a	 238±10d	 306±1b	 291±2c	 225±5e	
β-carotene bleaching inhibition  710±10b	 545±9d	 826±9a	 666±23c	 435±15e	
TBARS inhibition	 1.45±0.08c	 1.22±0.05d 2.38±0.20a 1.70±0.03b 1.07±0.10e 
Anti-inflammatory activity (EC50 values, µg/mL)   
NO production 6.77±0.13b 5.76±0.06c 5.81±0.94c 7.91±0.17a 4.85±0.02d 
 
EC50 values for antioxidant activity: sample concentration providing 50% of antioxidant activity 
or 0.5 of absorbance in the reducing power. Trolox EC50 values: 41 µg/mL (reducing power), 42 
µg/mL (DPPH scavenging activity), 18 µg/mL (β-carotene bleaching inhibition) and 23 µg/mL 
(TBARS inhibition).  
EC50 values for anti-inflammatory activity: sample concentration providing 50% of inhibition of 
the NO production in relation to negative control (100%). Dexamethasone EC50 value:15.5±1.96 
µg/mL. 
In each row different letters mean significant differences between samples (p<0.05).  
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Table 3 
 In vitro cytotoxic activity of the bee venom (BV) samples. 
 BV 1	 BV 2	 BV 3	 BV 4	 BV 5	
For human tumour cell lines (GI50 values, µg/mL)     
MCF-7 (breast carcinoma) 4.16±0.49a 4.44±0.43a 4.02±0.38a 4.51±0.21a 4.49±0.42a 
NCI-H460 (non-small cell lung 
carcinoma) 
16.00±2.34a 17.68±0.53a 18.18±0.86a 19.68±1.80a 17.98±0.86a 
HeLa (cervical carcinoma) 4.54±0.22ab 2.83±0.41c 4.41±0.01ab 3.51±0.81bc 4.80±0.15a 
HepG2 (hepatocellular carcinoma) 10.6±1.89a 12.19±1.40a 5.43±0.08c 6.55±0.11bc 9.85±0.36ab 
For non-tumor liver cells (GI50 values, µg/mL)     
PLP2 15.03±0.28a	 13.86±0.10a	 10.11±0.91b	 12.94±1.21ab	 14.66±0.66a	
 
GI50 values: sample concentration achieving 50% of growth inhibition in human tumour cell lines or in liver primary 
culture PLP2.Ellipticine GI50 values: 1.21 µg/mL (MCF-7), 1.03 µg/mL (NCI-H460), 0.91 µg/mL (HeLa), 1.10 
µg/mL (HepG2) and 2.29 µg/mL (PLP2).  


























Fig. 1.  
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